[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fr94e489u2DeVLpg6u-wt3uC0mR2ojCFg2CTwVesPqls":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":54,"rows":61},"University of Massachusetts, Worcester",[4],284,false,64,16,867790,5,231,[14,17,20,23,25,27,29,31],{"name":15,"count":16},"Obesity",12,{"name":18,"count":19},"Schizophrenia",9,{"name":21,"count":22},"Smoking Cessation",6,{"name":24,"count":22},"Schizoaffective Disorder",{"name":26,"count":22},"Cancer",{"name":28,"count":22},"Atrial Fibrillation",{"name":30,"count":22},"Cardiovascular Diseases",{"name":32,"count":11},"Depression",[34,39,44,49],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06174116","Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia","2026-12","Lumateperone",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04669457","Pediatric Delirium","2027-04-05","Intra-nasal Dexmedetomidine",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05403710","Botulinum Toxin Therapy in Hidradenitis Suppurativa","2028-04-30","Botulinum toxin",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT07520110","Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis","2029-03-15","Metformin",[55,56,57,58,59,60],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[62,86,104,127,161,183,220,247,265,291,309,327,353,371,395,421,448,473,497,521,548,572,609,635,663,681,699,732,769,801,819,837,855,873,898,923,941,966,984,1002,1028,1050,1084,1111,1136,1154,1172,1190,1214,1242,1260,1278,1296,1314,1332,1356,1379,1402,1424,1448,1480,1505,1530,1558,1583,1612,1630,1648,1666,1684,1710,1728,1746,1770,1788,1815],{"intervention":43,"totalTrials":63,"cells":64},1,{"EARLY_PHASE1":65,"PHASE1":68,"PHASE2":70,"PHASE3":72,"PHASE4":74,"NA":84},{"trials":66,"activeCount":67},[],0,{"trials":69,"activeCount":67},[],{"trials":71,"activeCount":67},[],{"trials":73,"activeCount":67},[],{"trials":75,"activeCount":63,"soonestReadout":42},[76],{"nctId":40,"briefTitle":41,"status":77,"phases":78,"primaryCompletion":42,"completion":42,"start":79,"enrollment":80,"conditions":81,"interventions":82},"ENROLLING_BY_INVITATION",[59],"2021-04-27",60,[41],[43,83],"Oral Midazolam",{"trials":85,"activeCount":67},[],{"intervention":83,"totalTrials":63,"cells":87},{"EARLY_PHASE1":88,"PHASE1":90,"PHASE2":92,"PHASE3":94,"PHASE4":96,"NA":102},{"trials":89,"activeCount":67},[],{"trials":91,"activeCount":67},[],{"trials":93,"activeCount":67},[],{"trials":95,"activeCount":67},[],{"trials":97,"activeCount":63,"soonestReadout":42},[98],{"nctId":40,"briefTitle":41,"status":77,"phases":99,"primaryCompletion":42,"completion":42,"start":79,"enrollment":80,"conditions":100,"interventions":101},[59],[41],[43,83],{"trials":103,"activeCount":67},[],{"intervention":38,"totalTrials":63,"cells":105},{"EARLY_PHASE1":106,"PHASE1":108,"PHASE2":110,"PHASE3":112,"PHASE4":114,"NA":125},{"trials":107,"activeCount":67},[],{"trials":109,"activeCount":67},[],{"trials":111,"activeCount":67},[],{"trials":113,"activeCount":67},[],{"trials":115,"activeCount":63,"soonestReadout":37},[116],{"nctId":35,"briefTitle":36,"status":117,"phases":118,"primaryCompletion":37,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":124},"RECRUITING",[59],"2027-03","2024-04-02",50,[18,123],"Schizo Affective Disorder",[38],{"trials":126,"activeCount":67},[],{"intervention":53,"totalTrials":128,"cells":129},2,{"EARLY_PHASE1":130,"PHASE1":132,"PHASE2":134,"PHASE3":136,"PHASE4":157,"NA":159},{"trials":131,"activeCount":67},[],{"trials":133,"activeCount":67},[],{"trials":135,"activeCount":67},[],{"trials":137,"activeCount":63,"soonestReadout":52},[138,146],{"nctId":50,"briefTitle":51,"status":139,"phases":140,"primaryCompletion":52,"completion":52,"start":141,"enrollment":142,"conditions":143,"interventions":145},"NOT_YET_RECRUITING",[58],"2026-08-01",800,[144],"Idiopathic Pulmonary Fibrosis",[53],{"nctId":147,"briefTitle":148,"status":149,"phases":150,"primaryCompletion":151,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":156},"NCT01334125","Adjunctive Metformin Therapy in Double Diabetes","COMPLETED",[58],"2014-12","2011-02",28,[155],"Diabetes Mellitus",[53],{"trials":158,"activeCount":67},[],{"trials":160,"activeCount":67},[],{"intervention":48,"totalTrials":63,"cells":162},{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":169,"PHASE4":171,"NA":173},{"trials":164,"activeCount":67},[],{"trials":166,"activeCount":67},[],{"trials":168,"activeCount":67},[],{"trials":170,"activeCount":67},[],{"trials":172,"activeCount":67},[],{"trials":174,"activeCount":63,"soonestReadout":47},[175],{"nctId":45,"briefTitle":46,"status":117,"phases":176,"primaryCompletion":47,"completion":47,"start":177,"enrollment":178,"conditions":179,"interventions":182},[],"2022-06-07",20,[180,181],"Hidradenitis Suppurativa","Hyperhidrosis",[48],{"intervention":184,"totalTrials":128,"cells":185},"Memantine",{"EARLY_PHASE1":186,"PHASE1":188,"PHASE2":190,"PHASE3":192,"PHASE4":205,"NA":218},{"trials":187,"activeCount":67},[],{"trials":189,"activeCount":67},[],{"trials":191,"activeCount":67},[],{"trials":193,"activeCount":67},[194],{"nctId":195,"briefTitle":196,"status":149,"phases":197,"primaryCompletion":198,"completion":199,"start":200,"enrollment":201,"conditions":202,"interventions":204},"NCT01052662","Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults",[57,58],"2013-06","2013-10","2009-10",87,[203],"Opioid Dependence",[184,184],{"trials":206,"activeCount":67},[207],{"nctId":208,"briefTitle":209,"status":149,"phases":210,"primaryCompletion":211,"completion":211,"start":212,"enrollment":213,"conditions":214,"interventions":216},"NCT00344682","Memantine Augmentation of Antidepressants",[59],"2011-12","2006-06",31,[215],"Depressive Disorder",[217],"memantine",{"trials":219,"activeCount":67},[],{"intervention":221,"totalTrials":63,"cells":222},"Exparel",{"EARLY_PHASE1":223,"PHASE1":225,"PHASE2":227,"PHASE3":229,"PHASE4":231,"NA":245},{"trials":224,"activeCount":67},[],{"trials":226,"activeCount":67},[],{"trials":228,"activeCount":67},[],{"trials":230,"activeCount":67},[],{"trials":232,"activeCount":67},[233],{"nctId":234,"briefTitle":235,"status":149,"phases":236,"primaryCompletion":237,"completion":238,"start":239,"enrollment":240,"conditions":241,"interventions":243},"NCT03289858","Randomized Controlled Trial for Exparel Hip Fracture",[59],"2019-01-01","2019-01-22","2017-09-01",55,[242],"Hip Fractures",[221,244],"Sodium Chloride",{"trials":246,"activeCount":67},[],{"intervention":244,"totalTrials":63,"cells":248},{"EARLY_PHASE1":249,"PHASE1":251,"PHASE2":253,"PHASE3":255,"PHASE4":257,"NA":263},{"trials":250,"activeCount":67},[],{"trials":252,"activeCount":67},[],{"trials":254,"activeCount":67},[],{"trials":256,"activeCount":67},[],{"trials":258,"activeCount":67},[259],{"nctId":234,"briefTitle":235,"status":149,"phases":260,"primaryCompletion":237,"completion":238,"start":239,"enrollment":240,"conditions":261,"interventions":262},[59],[242],[221,244],{"trials":264,"activeCount":67},[],{"intervention":266,"totalTrials":63,"cells":267},"Telmisartan",{"EARLY_PHASE1":268,"PHASE1":270,"PHASE2":272,"PHASE3":274,"PHASE4":276,"NA":289},{"trials":269,"activeCount":67},[],{"trials":271,"activeCount":67},[],{"trials":273,"activeCount":67},[],{"trials":275,"activeCount":67},[],{"trials":277,"activeCount":67},[278],{"nctId":279,"briefTitle":280,"status":149,"phases":281,"primaryCompletion":282,"completion":282,"start":283,"enrollment":284,"conditions":285,"interventions":286},"NCT00981526","Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia",[59],"2012-05","2009-03",66,[18,24],[266,287,288],"Clozapine","Olanzapine",{"trials":290,"activeCount":67},[],{"intervention":287,"totalTrials":63,"cells":292},{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":297,"PHASE3":299,"PHASE4":301,"NA":307},{"trials":294,"activeCount":67},[],{"trials":296,"activeCount":67},[],{"trials":298,"activeCount":67},[],{"trials":300,"activeCount":67},[],{"trials":302,"activeCount":67},[303],{"nctId":279,"briefTitle":280,"status":149,"phases":304,"primaryCompletion":282,"completion":282,"start":283,"enrollment":284,"conditions":305,"interventions":306},[59],[18,24],[266,287,288],{"trials":308,"activeCount":67},[],{"intervention":288,"totalTrials":63,"cells":310},{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":317,"PHASE4":319,"NA":325},{"trials":312,"activeCount":67},[],{"trials":314,"activeCount":67},[],{"trials":316,"activeCount":67},[],{"trials":318,"activeCount":67},[],{"trials":320,"activeCount":67},[321],{"nctId":279,"briefTitle":280,"status":149,"phases":322,"primaryCompletion":282,"completion":282,"start":283,"enrollment":284,"conditions":323,"interventions":324},[59],[18,24],[266,287,288],{"trials":326,"activeCount":67},[],{"intervention":328,"totalTrials":63,"cells":329},"Gadoterate meglumine",{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":336,"PHASE4":338,"NA":351},{"trials":331,"activeCount":67},[],{"trials":333,"activeCount":67},[],{"trials":335,"activeCount":67},[],{"trials":337,"activeCount":67},[],{"trials":339,"activeCount":67},[340],{"nctId":341,"briefTitle":342,"status":149,"phases":343,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":347,"interventions":349},"NCT03730051","Dotarem vs Gadobutrol Contrast for Breast MRI",[59],"2025-12-31","2021-03-01",300,[348],"Breast Diseases",[328,350],"Gadobutrol",{"trials":352,"activeCount":67},[],{"intervention":350,"totalTrials":63,"cells":354},{"EARLY_PHASE1":355,"PHASE1":357,"PHASE2":359,"PHASE3":361,"PHASE4":363,"NA":369},{"trials":356,"activeCount":67},[],{"trials":358,"activeCount":67},[],{"trials":360,"activeCount":67},[],{"trials":362,"activeCount":67},[],{"trials":364,"activeCount":67},[365],{"nctId":341,"briefTitle":342,"status":149,"phases":366,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":367,"interventions":368},[59],[348],[328,350],{"trials":370,"activeCount":67},[],{"intervention":372,"totalTrials":63,"cells":373},"salsalate",{"EARLY_PHASE1":374,"PHASE1":376,"PHASE2":378,"PHASE3":380,"PHASE4":382,"NA":393},{"trials":375,"activeCount":67},[],{"trials":377,"activeCount":67},[],{"trials":379,"activeCount":67},[],{"trials":381,"activeCount":67},[],{"trials":383,"activeCount":67},[384],{"nctId":385,"briefTitle":386,"status":149,"phases":387,"primaryCompletion":388,"completion":388,"start":389,"enrollment":390,"conditions":391,"interventions":392},"NCT01578486","Salsalate as an Adjunctive Treatment for Patients With Schizophrenia",[59],"2015-07","2011-06",17,[18,24],[372],{"trials":394,"activeCount":67},[],{"intervention":396,"totalTrials":63,"cells":397},"Potassium Iodide",{"EARLY_PHASE1":398,"PHASE1":400,"PHASE2":402,"PHASE3":404,"PHASE4":406,"NA":419},{"trials":399,"activeCount":67},[],{"trials":401,"activeCount":67},[],{"trials":403,"activeCount":67},[],{"trials":405,"activeCount":67},[],{"trials":407,"activeCount":67},[408],{"nctId":409,"briefTitle":410,"status":149,"phases":411,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":415,"interventions":418},"NCT00946296","Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease",[59],"2013-04","2005-04",36,[416,417],"Graves Disease","Hyperthyroidism",[396],{"trials":420,"activeCount":67},[],{"intervention":422,"totalTrials":63,"cells":423},"Tamsulosin Hydrochloride",{"EARLY_PHASE1":424,"PHASE1":426,"PHASE2":428,"PHASE3":430,"PHASE4":432,"NA":446},{"trials":425,"activeCount":67},[],{"trials":427,"activeCount":67},[],{"trials":429,"activeCount":67},[],{"trials":431,"activeCount":67},[],{"trials":433,"activeCount":67},[434],{"nctId":435,"briefTitle":436,"status":437,"phases":438,"primaryCompletion":439,"completion":439,"start":440,"enrollment":441,"conditions":442,"interventions":445},"NCT04994431","Post-Operative Urinary Retention (POUR) in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin","TERMINATED",[59],"2023-10-04","2021-08-01",109,[443,444],"Thoracic Diseases","Urinary Retention",[422],{"trials":447,"activeCount":67},[],{"intervention":449,"totalTrials":63,"cells":450},"Exenatide",{"EARLY_PHASE1":451,"PHASE1":453,"PHASE2":455,"PHASE3":457,"PHASE4":459,"NA":471},{"trials":452,"activeCount":67},[],{"trials":454,"activeCount":67},[],{"trials":456,"activeCount":67},[],{"trials":458,"activeCount":67},[],{"trials":460,"activeCount":67},[461],{"nctId":462,"briefTitle":463,"status":149,"phases":464,"primaryCompletion":465,"completion":466,"start":467,"enrollment":468,"conditions":469,"interventions":470},"NCT02417142","Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia",[59],"2019-07","2020-07","2014-09",70,[18,24],[449],{"trials":472,"activeCount":67},[],{"intervention":474,"totalTrials":63,"cells":475},"Brexpiprazole",{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":484,"NA":495},{"trials":477,"activeCount":67},[],{"trials":479,"activeCount":67},[],{"trials":481,"activeCount":67},[],{"trials":483,"activeCount":67},[],{"trials":485,"activeCount":67},[486],{"nctId":487,"briefTitle":488,"status":149,"phases":489,"primaryCompletion":490,"completion":490,"start":491,"enrollment":121,"conditions":492,"interventions":494},"NCT03526354","Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder",[59],"2024-02-29","2018-06-19",[18,24,493],"Substance Use Disorders",[474],{"trials":496,"activeCount":67},[],{"intervention":498,"totalTrials":63,"cells":499},"Insulin",{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":504,"PHASE3":506,"PHASE4":508,"NA":519},{"trials":501,"activeCount":67},[],{"trials":503,"activeCount":67},[],{"trials":505,"activeCount":67},[],{"trials":507,"activeCount":67},[],{"trials":509,"activeCount":67},[510],{"nctId":511,"briefTitle":512,"status":149,"phases":513,"primaryCompletion":514,"completion":514,"start":515,"enrollment":516,"conditions":517,"interventions":518},"NCT00646581","Effect of Single Dose Intranasal Insulin On Cognitive Function",[59],"2010-01","2006-10",30,[18,24],[498],{"trials":520,"activeCount":67},[],{"intervention":522,"totalTrials":63,"cells":523},"Bupivacaine Liposome",{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":528,"PHASE3":530,"PHASE4":532,"NA":546},{"trials":525,"activeCount":67},[],{"trials":527,"activeCount":67},[],{"trials":529,"activeCount":67},[],{"trials":531,"activeCount":67},[],{"trials":533,"activeCount":67},[534],{"nctId":535,"briefTitle":536,"status":537,"phases":538,"primaryCompletion":539,"completion":539,"start":540,"enrollment":67,"conditions":541,"interventions":545},"NCT04134442","Improving Pain Management After Total Shoulder Replacement Using Bupivacaine Liposome","WITHDRAWN",[59],"2021-09-23","2019-12-09",[542,543,544],"Osteoarthritis of the Shoulder","Shoulder Pain","Pain, Postoperative",[522],{"trials":547,"activeCount":67},[],{"intervention":549,"totalTrials":63,"cells":550},"Insulin or Placebo",{"EARLY_PHASE1":551,"PHASE1":553,"PHASE2":555,"PHASE3":557,"PHASE4":559,"NA":570},{"trials":552,"activeCount":67},[],{"trials":554,"activeCount":67},[],{"trials":556,"activeCount":67},[],{"trials":558,"activeCount":67},[],{"trials":560,"activeCount":67},[561],{"nctId":562,"briefTitle":563,"status":149,"phases":564,"primaryCompletion":565,"completion":565,"start":566,"enrollment":567,"conditions":568,"interventions":569},"NCT00575666","Intranasal Insulin Treatment in Patients With Schizophrenia",[59],"2010-09","2007-12",45,[18],[549],{"trials":571,"activeCount":67},[],{"intervention":573,"totalTrials":128,"cells":574},"Phenazopyridine",{"EARLY_PHASE1":575,"PHASE1":577,"PHASE2":579,"PHASE3":581,"PHASE4":605,"NA":607},{"trials":576,"activeCount":67},[],{"trials":578,"activeCount":67},[],{"trials":580,"activeCount":67},[],{"trials":582,"activeCount":67},[583,594],{"nctId":584,"briefTitle":585,"status":149,"phases":586,"primaryCompletion":587,"completion":587,"start":588,"enrollment":589,"conditions":590,"interventions":593},"NCT02806713","The Effect of Oral PhenazopyrIdine on Perioperative Voiding After Mid-urethral sliNg (EPIPhANy Study)",[58],"2017-08","2016-02",92,[591,592],"Dysfunctional Voiding","Postoperative Pain",[573],{"nctId":595,"briefTitle":596,"status":149,"phases":597,"primaryCompletion":598,"completion":599,"start":600,"enrollment":601,"conditions":602,"interventions":604},"NCT03065075","Effect of Phenazopyridine on Prolapse Surgery Voiding Trials",[58],"2018-08-28","2019-02-28","2017-02-01",152,[603],"Urinary Retention Postoperative",[573],{"trials":606,"activeCount":67},[],{"trials":608,"activeCount":67},[],{"intervention":610,"totalTrials":63,"cells":611},"Montelukast",{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":618,"PHASE4":631,"NA":633},{"trials":613,"activeCount":67},[],{"trials":615,"activeCount":67},[],{"trials":617,"activeCount":67},[],{"trials":619,"activeCount":67},[620],{"nctId":621,"briefTitle":622,"status":149,"phases":623,"primaryCompletion":624,"completion":624,"start":625,"enrollment":626,"conditions":627,"interventions":630},"NCT00115297","Montelukast for Early Life Wheezing",[57,58],"2016-10","2004-09",62,[628,629],"Lung Diseases","Asthma",[610],{"trials":632,"activeCount":67},[],{"trials":634,"activeCount":67},[],{"intervention":636,"totalTrials":63,"cells":637},"Ropivacaine injection Location 1",{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":644,"PHASE4":659,"NA":661},{"trials":639,"activeCount":67},[],{"trials":641,"activeCount":67},[],{"trials":643,"activeCount":67},[],{"trials":645,"activeCount":67},[646],{"nctId":647,"briefTitle":648,"status":437,"phases":649,"primaryCompletion":650,"completion":650,"start":651,"enrollment":19,"conditions":652,"interventions":656},"NCT04588389","Comparison of Quadratus Lumborum Block Types",[58],"2021-05-14","2020-12-01",[653,654,655],"Pain","Opioid Use","Lumbar Disc Herniation",[636,657,658],"Ropivacaine injection Location 2","Multimodal Pharmacological Management",{"trials":660,"activeCount":67},[],{"trials":662,"activeCount":67},[],{"intervention":657,"totalTrials":63,"cells":664},{"EARLY_PHASE1":665,"PHASE1":667,"PHASE2":669,"PHASE3":671,"PHASE4":677,"NA":679},{"trials":666,"activeCount":67},[],{"trials":668,"activeCount":67},[],{"trials":670,"activeCount":67},[],{"trials":672,"activeCount":67},[673],{"nctId":647,"briefTitle":648,"status":437,"phases":674,"primaryCompletion":650,"completion":650,"start":651,"enrollment":19,"conditions":675,"interventions":676},[58],[653,654,655],[636,657,658],{"trials":678,"activeCount":67},[],{"trials":680,"activeCount":67},[],{"intervention":658,"totalTrials":63,"cells":682},{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":689,"PHASE4":695,"NA":697},{"trials":684,"activeCount":67},[],{"trials":686,"activeCount":67},[],{"trials":688,"activeCount":67},[],{"trials":690,"activeCount":67},[691],{"nctId":647,"briefTitle":648,"status":437,"phases":692,"primaryCompletion":650,"completion":650,"start":651,"enrollment":19,"conditions":693,"interventions":694},[58],[653,654,655],[636,657,658],{"trials":696,"activeCount":67},[],{"trials":698,"activeCount":67},[],{"intervention":700,"totalTrials":128,"cells":701},"Dantrolene",{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":726,"PHASE4":728,"NA":730},{"trials":703,"activeCount":67},[],{"trials":705,"activeCount":67},[],{"trials":707,"activeCount":67},[708,717],{"nctId":709,"briefTitle":710,"status":149,"phases":711,"primaryCompletion":200,"completion":200,"start":712,"enrollment":713,"conditions":714,"interventions":716},"NCT00964548","Safety Study of Dantrolene to Treat Cerebral Vasospasm After Subarachnoid Hemorrhage",[56,57],"2007-07",10,[715],"Cerebral Vasospasm After Subarachnoid Hemorrhage",[700,700],{"nctId":718,"briefTitle":719,"status":149,"phases":720,"primaryCompletion":721,"completion":199,"start":200,"enrollment":213,"conditions":722,"interventions":725},"NCT01024972","Safety Study of Dantrolene in Subarachnoid Hemorrhage",[56,57],"2013-07",[723,724],"Subarachnoid Hemorrhage","Cerebral Vasospasm",[700],{"trials":727,"activeCount":67},[],{"trials":729,"activeCount":67},[],{"trials":731,"activeCount":67},[],{"intervention":733,"totalTrials":128,"cells":734},"L-arginine",{"EARLY_PHASE1":735,"PHASE1":737,"PHASE2":739,"PHASE3":763,"PHASE4":765,"NA":767},{"trials":736,"activeCount":67},[],{"trials":738,"activeCount":67},[],{"trials":740,"activeCount":67},[741,750],{"nctId":742,"briefTitle":743,"status":537,"phases":744,"primaryCompletion":745,"completion":745,"start":746,"enrollment":67,"conditions":747,"interventions":748},"NCT04054973","L-arginine Study for Persistent Symptoms of Schizophrenia",[57],"2021-12-31","2019-09-11",[123,18],[733,749],"Sapropterin Dihydrochloride",{"nctId":751,"briefTitle":752,"status":149,"phases":753,"primaryCompletion":754,"completion":754,"start":755,"enrollment":756,"conditions":757,"interventions":759},"NCT01439555","Endothelial Facilitation in Alzheimer's Disease",[57],"2017-11","2011-11",11,[758],"Alzheimer's Disease",[760,761,762],"Simvastatin","L-Arginine","Tetrahydrobiopterin",{"trials":764,"activeCount":67},[],{"trials":766,"activeCount":67},[],{"trials":768,"activeCount":67},[],{"intervention":770,"totalTrials":63,"cells":771},"Isoniazid",{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":776,"PHASE3":795,"PHASE4":797,"NA":799},{"trials":773,"activeCount":67},[],{"trials":775,"activeCount":67},[],{"trials":777,"activeCount":67},[778],{"nctId":779,"briefTitle":780,"status":149,"phases":781,"primaryCompletion":782,"completion":783,"start":784,"enrollment":785,"conditions":786,"interventions":790},"NCT04930744","Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)",[57],"2025-04-29","2025-08-15","2021-08-26",112,[787,788,789],"Tuberculosis","Pulmonary Tuberculosis","HIV Coinfection",[770,791,792,793,794],"Rifampicin","Ethambutol","Pyrazinamide","Metformin hydrochoride",{"trials":796,"activeCount":67},[],{"trials":798,"activeCount":67},[],{"trials":800,"activeCount":67},[],{"intervention":791,"totalTrials":63,"cells":802},{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":807,"PHASE3":813,"PHASE4":815,"NA":817},{"trials":804,"activeCount":67},[],{"trials":806,"activeCount":67},[],{"trials":808,"activeCount":67},[809],{"nctId":779,"briefTitle":780,"status":149,"phases":810,"primaryCompletion":782,"completion":783,"start":784,"enrollment":785,"conditions":811,"interventions":812},[57],[787,788,789],[770,791,792,793,794],{"trials":814,"activeCount":67},[],{"trials":816,"activeCount":67},[],{"trials":818,"activeCount":67},[],{"intervention":792,"totalTrials":63,"cells":820},{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":825,"PHASE3":831,"PHASE4":833,"NA":835},{"trials":822,"activeCount":67},[],{"trials":824,"activeCount":67},[],{"trials":826,"activeCount":67},[827],{"nctId":779,"briefTitle":780,"status":149,"phases":828,"primaryCompletion":782,"completion":783,"start":784,"enrollment":785,"conditions":829,"interventions":830},[57],[787,788,789],[770,791,792,793,794],{"trials":832,"activeCount":67},[],{"trials":834,"activeCount":67},[],{"trials":836,"activeCount":67},[],{"intervention":793,"totalTrials":63,"cells":838},{"EARLY_PHASE1":839,"PHASE1":841,"PHASE2":843,"PHASE3":849,"PHASE4":851,"NA":853},{"trials":840,"activeCount":67},[],{"trials":842,"activeCount":67},[],{"trials":844,"activeCount":67},[845],{"nctId":779,"briefTitle":780,"status":149,"phases":846,"primaryCompletion":782,"completion":783,"start":784,"enrollment":785,"conditions":847,"interventions":848},[57],[787,788,789],[770,791,792,793,794],{"trials":850,"activeCount":67},[],{"trials":852,"activeCount":67},[],{"trials":854,"activeCount":67},[],{"intervention":794,"totalTrials":63,"cells":856},{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":867,"PHASE4":869,"NA":871},{"trials":858,"activeCount":67},[],{"trials":860,"activeCount":67},[],{"trials":862,"activeCount":67},[863],{"nctId":779,"briefTitle":780,"status":149,"phases":864,"primaryCompletion":782,"completion":783,"start":784,"enrollment":785,"conditions":865,"interventions":866},[57],[787,788,789],[770,791,792,793,794],{"trials":868,"activeCount":67},[],{"trials":870,"activeCount":67},[],{"trials":872,"activeCount":67},[],{"intervention":874,"totalTrials":63,"cells":875},"Metformin Hydrochloride",{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":892,"PHASE4":894,"NA":896},{"trials":877,"activeCount":67},[],{"trials":879,"activeCount":67},[],{"trials":881,"activeCount":67},[882],{"nctId":883,"briefTitle":884,"status":537,"phases":885,"primaryCompletion":886,"completion":887,"start":888,"enrollment":67,"conditions":889,"interventions":891},"NCT05607316","Evaluating the Efficacy and Safety of Metformin in Vitiligo",[57],"2028-06-30","2028-11-01","2025-07",[890],"Vitiligo",[874],{"trials":893,"activeCount":67},[],{"trials":895,"activeCount":67},[],{"trials":897,"activeCount":67},[],{"intervention":899,"totalTrials":63,"cells":900},"Sulforaphane",{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":917,"PHASE4":919,"NA":921},{"trials":902,"activeCount":67},[],{"trials":904,"activeCount":67},[],{"trials":906,"activeCount":67},[907],{"nctId":908,"briefTitle":909,"status":149,"phases":910,"primaryCompletion":911,"completion":912,"start":913,"enrollment":80,"conditions":914,"interventions":916},"NCT02561481","Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD)",[56,57],"2018-12","2020-01","2015-12",[915],"Autism Spectrum Disorder",[899],{"trials":918,"activeCount":67},[],{"trials":920,"activeCount":67},[],{"trials":922,"activeCount":67},[],{"intervention":749,"totalTrials":63,"cells":924},{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":935,"PHASE4":937,"NA":939},{"trials":926,"activeCount":67},[],{"trials":928,"activeCount":67},[],{"trials":930,"activeCount":67},[931],{"nctId":742,"briefTitle":743,"status":537,"phases":932,"primaryCompletion":745,"completion":745,"start":746,"enrollment":67,"conditions":933,"interventions":934},[57],[123,18],[733,749],{"trials":936,"activeCount":67},[],{"trials":938,"activeCount":67},[],{"trials":940,"activeCount":67},[],{"intervention":942,"totalTrials":63,"cells":943},"intravenous immunoglobulin",{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":948,"PHASE3":960,"PHASE4":962,"NA":964},{"trials":945,"activeCount":67},[],{"trials":947,"activeCount":67},[],{"trials":949,"activeCount":67},[950],{"nctId":951,"briefTitle":952,"status":149,"phases":953,"primaryCompletion":954,"completion":955,"start":956,"enrollment":19,"conditions":957,"interventions":959},"NCT00750867","Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins",[57],"2009-09","2012-12","2008-06",[958],"Multiple System Atrophy",[942],{"trials":961,"activeCount":67},[],{"trials":963,"activeCount":67},[],{"trials":965,"activeCount":67},[],{"intervention":760,"totalTrials":63,"cells":967},{"EARLY_PHASE1":968,"PHASE1":970,"PHASE2":972,"PHASE3":978,"PHASE4":980,"NA":982},{"trials":969,"activeCount":67},[],{"trials":971,"activeCount":67},[],{"trials":973,"activeCount":67},[974],{"nctId":751,"briefTitle":752,"status":149,"phases":975,"primaryCompletion":754,"completion":754,"start":755,"enrollment":756,"conditions":976,"interventions":977},[57],[758],[760,761,762],{"trials":979,"activeCount":67},[],{"trials":981,"activeCount":67},[],{"trials":983,"activeCount":67},[],{"intervention":762,"totalTrials":63,"cells":985},{"EARLY_PHASE1":986,"PHASE1":988,"PHASE2":990,"PHASE3":996,"PHASE4":998,"NA":1000},{"trials":987,"activeCount":67},[],{"trials":989,"activeCount":67},[],{"trials":991,"activeCount":67},[992],{"nctId":751,"briefTitle":752,"status":149,"phases":993,"primaryCompletion":754,"completion":754,"start":755,"enrollment":756,"conditions":994,"interventions":995},[57],[758],[760,761,762],{"trials":997,"activeCount":67},[],{"trials":999,"activeCount":67},[],{"trials":1001,"activeCount":67},[],{"intervention":1003,"totalTrials":63,"cells":1004},"Rosiglitazone",{"EARLY_PHASE1":1005,"PHASE1":1007,"PHASE2":1009,"PHASE3":1022,"PHASE4":1024,"NA":1026},{"trials":1006,"activeCount":67},[],{"trials":1008,"activeCount":67},[],{"trials":1010,"activeCount":67},[1011],{"nctId":1012,"briefTitle":1013,"status":149,"phases":1014,"primaryCompletion":1015,"completion":1015,"start":1016,"enrollment":1017,"conditions":1018,"interventions":1021},"NCT01150981","Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue",[57],"2010-04","2006-11",35,[1019,1020],"Metabolic Syndrome","Insulin Resistance",[1003],{"trials":1023,"activeCount":67},[],{"trials":1025,"activeCount":67},[],{"trials":1027,"activeCount":67},[],{"intervention":1029,"totalTrials":63,"cells":1030},"Gemcitabine\u002FFluorouracil with External Beam Radiation",{"EARLY_PHASE1":1031,"PHASE1":1033,"PHASE2":1035,"PHASE3":1044,"PHASE4":1046,"NA":1048},{"trials":1032,"activeCount":67},[],{"trials":1034,"activeCount":67},[],{"trials":1036,"activeCount":67},[1037],{"nctId":1038,"briefTitle":1039,"status":149,"phases":1040,"primaryCompletion":151,"completion":151,"start":212,"enrollment":756,"conditions":1041,"interventions":1043},"NCT00424827","A Trial of Chemo & Radiation Therapy for Pancreatic Cancer",[57],[1042],"Pancreatic Cancer",[1029],{"trials":1045,"activeCount":67},[],{"trials":1047,"activeCount":67},[],{"trials":1049,"activeCount":67},[],{"intervention":1051,"totalTrials":128,"cells":1052},"Zileuton",{"EARLY_PHASE1":1053,"PHASE1":1055,"PHASE2":1076,"PHASE3":1078,"PHASE4":1080,"NA":1082},{"trials":1054,"activeCount":67},[],{"trials":1056,"activeCount":67},[1057,1069],{"nctId":1058,"briefTitle":1059,"status":437,"phases":1060,"primaryCompletion":1061,"completion":1061,"start":1062,"enrollment":128,"conditions":1063,"interventions":1065},"NCT02047149","Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia",[56],"2016-06","2014-01",[1064],"Chronic Myelogenous Leukemia",[1051,1066,1067,1068],"Dosing with Zileuton\u002FDasatinib in CML","Daily dosing of Zileuton\u002FDasatinib","Daily dosing with Zileuton\u002FDasatinib for CML",{"nctId":1070,"briefTitle":1071,"status":437,"phases":1072,"primaryCompletion":1073,"completion":151,"start":514,"enrollment":128,"conditions":1074,"interventions":1075},"NCT01130688","Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.",[56],"2012-10",[1064],[1051],{"trials":1077,"activeCount":67},[],{"trials":1079,"activeCount":67},[],{"trials":1081,"activeCount":67},[],{"trials":1083,"activeCount":67},[],{"intervention":1085,"totalTrials":63,"cells":1086},"Oxaliplatin",{"EARLY_PHASE1":1087,"PHASE1":1089,"PHASE2":1103,"PHASE3":1105,"PHASE4":1107,"NA":1109},{"trials":1088,"activeCount":67},[],{"trials":1090,"activeCount":67},[1091],{"nctId":1092,"briefTitle":1093,"status":149,"phases":1094,"primaryCompletion":1095,"completion":1095,"start":1096,"enrollment":1097,"conditions":1098,"interventions":1102},"NCT02833753","Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI",[56],"2022-02","2016-07",14,[1099,1100,1101],"Colorectal Cancer","Appendix Cancer","Peritoneal Carcinomatosis",[1085],{"trials":1104,"activeCount":67},[],{"trials":1106,"activeCount":67},[],{"trials":1108,"activeCount":67},[],{"trials":1110,"activeCount":67},[],{"intervention":1112,"totalTrials":63,"cells":1113},"AdKCNH2-G628S",{"EARLY_PHASE1":1114,"PHASE1":1116,"PHASE2":1128,"PHASE3":1130,"PHASE4":1132,"NA":1134},{"trials":1115,"activeCount":67},[],{"trials":1117,"activeCount":67},[1118],{"nctId":1119,"briefTitle":1120,"status":537,"phases":1121,"primaryCompletion":1122,"completion":1123,"start":1124,"enrollment":67,"conditions":1125,"interventions":1127},"NCT05223725","Gene Therapy for Post-Operative Atrial Fibrillation",[56],"2025-08","2026-08","2023-10-01",[28,1126],"Post-operative Atrial Fibrillation",[1112],{"trials":1129,"activeCount":67},[],{"trials":1131,"activeCount":67},[],{"trials":1133,"activeCount":67},[],{"trials":1135,"activeCount":67},[],{"intervention":1066,"totalTrials":63,"cells":1137},{"EARLY_PHASE1":1138,"PHASE1":1140,"PHASE2":1146,"PHASE3":1148,"PHASE4":1150,"NA":1152},{"trials":1139,"activeCount":67},[],{"trials":1141,"activeCount":67},[1142],{"nctId":1058,"briefTitle":1059,"status":437,"phases":1143,"primaryCompletion":1061,"completion":1061,"start":1062,"enrollment":128,"conditions":1144,"interventions":1145},[56],[1064],[1051,1066,1067,1068],{"trials":1147,"activeCount":67},[],{"trials":1149,"activeCount":67},[],{"trials":1151,"activeCount":67},[],{"trials":1153,"activeCount":67},[],{"intervention":1067,"totalTrials":63,"cells":1155},{"EARLY_PHASE1":1156,"PHASE1":1158,"PHASE2":1164,"PHASE3":1166,"PHASE4":1168,"NA":1170},{"trials":1157,"activeCount":67},[],{"trials":1159,"activeCount":67},[1160],{"nctId":1058,"briefTitle":1059,"status":437,"phases":1161,"primaryCompletion":1061,"completion":1061,"start":1062,"enrollment":128,"conditions":1162,"interventions":1163},[56],[1064],[1051,1066,1067,1068],{"trials":1165,"activeCount":67},[],{"trials":1167,"activeCount":67},[],{"trials":1169,"activeCount":67},[],{"trials":1171,"activeCount":67},[],{"intervention":1068,"totalTrials":63,"cells":1173},{"EARLY_PHASE1":1174,"PHASE1":1176,"PHASE2":1182,"PHASE3":1184,"PHASE4":1186,"NA":1188},{"trials":1175,"activeCount":67},[],{"trials":1177,"activeCount":67},[1178],{"nctId":1058,"briefTitle":1059,"status":437,"phases":1179,"primaryCompletion":1061,"completion":1061,"start":1062,"enrollment":128,"conditions":1180,"interventions":1181},[56],[1064],[1051,1066,1067,1068],{"trials":1183,"activeCount":67},[],{"trials":1185,"activeCount":67},[],{"trials":1187,"activeCount":67},[],{"trials":1189,"activeCount":67},[],{"intervention":1191,"totalTrials":63,"cells":1192},"Nutropin AQ",{"EARLY_PHASE1":1193,"PHASE1":1195,"PHASE2":1206,"PHASE3":1208,"PHASE4":1210,"NA":1212},{"trials":1194,"activeCount":67},[],{"trials":1196,"activeCount":67},[1197],{"nctId":1198,"briefTitle":1199,"status":437,"phases":1200,"primaryCompletion":1201,"completion":1201,"start":1202,"enrollment":11,"conditions":1203,"interventions":1205},"NCT00803179","Growth Hormone Therapy for Wasting in Cystic Fibrosis",[56],"2012-03","2008-11",[1204],"Cystic Fibrosis",[1191],{"trials":1207,"activeCount":67},[],{"trials":1209,"activeCount":67},[],{"trials":1211,"activeCount":67},[],{"trials":1213,"activeCount":67},[],{"intervention":1215,"totalTrials":63,"cells":1216},"Bortezomib 1.3 mg\u002Fm2",{"EARLY_PHASE1":1217,"PHASE1":1219,"PHASE2":1234,"PHASE3":1236,"PHASE4":1238,"NA":1240},{"trials":1218,"activeCount":67},[],{"trials":1220,"activeCount":67},[1221],{"nctId":1222,"briefTitle":1223,"status":437,"phases":1224,"primaryCompletion":1225,"completion":1225,"start":212,"enrollment":16,"conditions":1226,"interventions":1228},"NCT00424840","Phase I\u002FII Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy",[56],"2014-03",[1227],"Lung Cancer",[1215,1229,1230,1231,1232,1233],"Bortezomib 1.6 mg\u002Fm2","Bortezomib 1.8 mg\u002Fm2","Carboplatin AUC 6","Bevacizumab","Taxotere",{"trials":1235,"activeCount":67},[],{"trials":1237,"activeCount":67},[],{"trials":1239,"activeCount":67},[],{"trials":1241,"activeCount":67},[],{"intervention":1229,"totalTrials":63,"cells":1243},{"EARLY_PHASE1":1244,"PHASE1":1246,"PHASE2":1252,"PHASE3":1254,"PHASE4":1256,"NA":1258},{"trials":1245,"activeCount":67},[],{"trials":1247,"activeCount":67},[1248],{"nctId":1222,"briefTitle":1223,"status":437,"phases":1249,"primaryCompletion":1225,"completion":1225,"start":212,"enrollment":16,"conditions":1250,"interventions":1251},[56],[1227],[1215,1229,1230,1231,1232,1233],{"trials":1253,"activeCount":67},[],{"trials":1255,"activeCount":67},[],{"trials":1257,"activeCount":67},[],{"trials":1259,"activeCount":67},[],{"intervention":1230,"totalTrials":63,"cells":1261},{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1270,"PHASE3":1272,"PHASE4":1274,"NA":1276},{"trials":1263,"activeCount":67},[],{"trials":1265,"activeCount":67},[1266],{"nctId":1222,"briefTitle":1223,"status":437,"phases":1267,"primaryCompletion":1225,"completion":1225,"start":212,"enrollment":16,"conditions":1268,"interventions":1269},[56],[1227],[1215,1229,1230,1231,1232,1233],{"trials":1271,"activeCount":67},[],{"trials":1273,"activeCount":67},[],{"trials":1275,"activeCount":67},[],{"trials":1277,"activeCount":67},[],{"intervention":1231,"totalTrials":63,"cells":1279},{"EARLY_PHASE1":1280,"PHASE1":1282,"PHASE2":1288,"PHASE3":1290,"PHASE4":1292,"NA":1294},{"trials":1281,"activeCount":67},[],{"trials":1283,"activeCount":67},[1284],{"nctId":1222,"briefTitle":1223,"status":437,"phases":1285,"primaryCompletion":1225,"completion":1225,"start":212,"enrollment":16,"conditions":1286,"interventions":1287},[56],[1227],[1215,1229,1230,1231,1232,1233],{"trials":1289,"activeCount":67},[],{"trials":1291,"activeCount":67},[],{"trials":1293,"activeCount":67},[],{"trials":1295,"activeCount":67},[],{"intervention":1232,"totalTrials":63,"cells":1297},{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1306,"PHASE3":1308,"PHASE4":1310,"NA":1312},{"trials":1299,"activeCount":67},[],{"trials":1301,"activeCount":67},[1302],{"nctId":1222,"briefTitle":1223,"status":437,"phases":1303,"primaryCompletion":1225,"completion":1225,"start":212,"enrollment":16,"conditions":1304,"interventions":1305},[56],[1227],[1215,1229,1230,1231,1232,1233],{"trials":1307,"activeCount":67},[],{"trials":1309,"activeCount":67},[],{"trials":1311,"activeCount":67},[],{"trials":1313,"activeCount":67},[],{"intervention":1233,"totalTrials":63,"cells":1315},{"EARLY_PHASE1":1316,"PHASE1":1318,"PHASE2":1324,"PHASE3":1326,"PHASE4":1328,"NA":1330},{"trials":1317,"activeCount":67},[],{"trials":1319,"activeCount":67},[1320],{"nctId":1222,"briefTitle":1223,"status":437,"phases":1321,"primaryCompletion":1225,"completion":1225,"start":212,"enrollment":16,"conditions":1322,"interventions":1323},[56],[1227],[1215,1229,1230,1231,1232,1233],{"trials":1325,"activeCount":67},[],{"trials":1327,"activeCount":67},[],{"trials":1329,"activeCount":67},[],{"trials":1331,"activeCount":67},[],{"intervention":1333,"totalTrials":63,"cells":1334},"rAAV1-CB-hAAT",{"EARLY_PHASE1":1335,"PHASE1":1337,"PHASE2":1348,"PHASE3":1350,"PHASE4":1352,"NA":1354},{"trials":1336,"activeCount":67},[],{"trials":1338,"activeCount":67},[1339],{"nctId":1340,"briefTitle":1341,"status":149,"phases":1342,"primaryCompletion":1343,"completion":1343,"start":1344,"enrollment":19,"conditions":1345,"interventions":1347},"NCT00430768","Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) Deficiency",[56],"2015-01","2006-02",[1346],"Alpha 1-Antitrypsin Deficiency",[1333],{"trials":1349,"activeCount":67},[],{"trials":1351,"activeCount":67},[],{"trials":1353,"activeCount":67},[],{"trials":1355,"activeCount":67},[],{"intervention":1357,"totalTrials":63,"cells":1358},"Antimelanoma injection of GSL alpha-Gal",{"EARLY_PHASE1":1359,"PHASE1":1361,"PHASE2":1371,"PHASE3":1373,"PHASE4":1375,"NA":1377},{"trials":1360,"activeCount":67},[],{"trials":1362,"activeCount":67},[1363],{"nctId":1364,"briefTitle":1365,"status":149,"phases":1366,"primaryCompletion":1225,"completion":1225,"start":1367,"enrollment":16,"conditions":1368,"interventions":1370},"NCT00668512","Intratumoral Injection Of Alpha-Gal Glycosphingolipids",[56],"2007-03",[1369],"Metastatic Melanoma",[1357],{"trials":1372,"activeCount":67},[],{"trials":1374,"activeCount":67},[],{"trials":1376,"activeCount":67},[],{"trials":1378,"activeCount":67},[],{"intervention":1380,"totalTrials":63,"cells":1381},"Alpha-Gal Glycosphingolipid",{"EARLY_PHASE1":1382,"PHASE1":1384,"PHASE2":1394,"PHASE3":1396,"PHASE4":1398,"NA":1400},{"trials":1383,"activeCount":67},[],{"trials":1385,"activeCount":67},[1386],{"nctId":1387,"briefTitle":1388,"status":149,"phases":1389,"primaryCompletion":1390,"completion":1390,"start":712,"enrollment":756,"conditions":1391,"interventions":1393},"NCT00668382","Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection",[56],"2011-07",[1392],"Neoplasm Metastases",[1380],{"trials":1395,"activeCount":67},[],{"trials":1397,"activeCount":67},[],{"trials":1399,"activeCount":67},[],{"trials":1401,"activeCount":67},[],{"intervention":1403,"totalTrials":63,"cells":1404},"rAAV2-CB-hAAT Gene Vector",{"EARLY_PHASE1":1405,"PHASE1":1414,"PHASE2":1416,"PHASE3":1418,"PHASE4":1420,"NA":1422},{"trials":1406,"activeCount":67},[1407],{"nctId":1408,"briefTitle":1409,"status":149,"phases":1410,"primaryCompletion":515,"completion":912,"start":1411,"enrollment":16,"conditions":1412,"interventions":1413},"NCT00377416","Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency",[55],"2004-03",[1346],[1403],{"trials":1415,"activeCount":67},[],{"trials":1417,"activeCount":67},[],{"trials":1419,"activeCount":67},[],{"trials":1421,"activeCount":67},[],{"trials":1423,"activeCount":67},[],{"intervention":1425,"totalTrials":63,"cells":1426},"Gabapentin",{"EARLY_PHASE1":1427,"PHASE1":1438,"PHASE2":1440,"PHASE3":1442,"PHASE4":1444,"NA":1446},{"trials":1428,"activeCount":67},[1429],{"nctId":1430,"briefTitle":1431,"status":149,"phases":1432,"primaryCompletion":1433,"completion":1433,"start":1434,"enrollment":1435,"conditions":1436,"interventions":1437},"NCT03589898","Study of Neuroimaging Biomarkers of Social Cognition Deficits in Adolescents (Age 13-17) With Autism Spectrum Disorder and Effects of Gabapentin",[55],"2022-08-31","2017-09-14",19,[915],[1425],{"trials":1439,"activeCount":67},[],{"trials":1441,"activeCount":67},[],{"trials":1443,"activeCount":67},[],{"trials":1445,"activeCount":67},[],{"trials":1447,"activeCount":67},[],{"intervention":1449,"totalTrials":128,"cells":1450},"Hyperpolarized Helium-3",{"EARLY_PHASE1":1451,"PHASE1":1453,"PHASE2":1455,"PHASE3":1457,"PHASE4":1459,"NA":1461},{"trials":1452,"activeCount":67},[],{"trials":1454,"activeCount":67},[],{"trials":1456,"activeCount":67},[],{"trials":1458,"activeCount":67},[],{"trials":1460,"activeCount":67},[],{"trials":1462,"activeCount":67},[1463,1472],{"nctId":1464,"briefTitle":1465,"status":437,"phases":1466,"primaryCompletion":1467,"completion":1467,"start":1202,"enrollment":1097,"conditions":1468,"interventions":1471},"NCT00846573","Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders",[60],"2011-04",[1469,1204,629,1470],"COPD","Healthy",[1449],{"nctId":1473,"briefTitle":1474,"status":149,"phases":1475,"primaryCompletion":1467,"completion":1467,"start":1202,"enrollment":9,"conditions":1476,"interventions":1478},"NCT00846287","Assessment of Arformoterol for Chronic Obstructive Pulmonary Disease (COPD) Using Hyperpolarized 3He MRI",[60],[1477],"Chronic Obstructive Pulmonary Disease",[1449,1479],"Aformoterol",{"intervention":1481,"totalTrials":63,"cells":1482},"Vitamin D3, Cholecalciferol",{"EARLY_PHASE1":1483,"PHASE1":1485,"PHASE2":1487,"PHASE3":1489,"PHASE4":1491,"NA":1493},{"trials":1484,"activeCount":67},[],{"trials":1486,"activeCount":67},[],{"trials":1488,"activeCount":67},[],{"trials":1490,"activeCount":67},[],{"trials":1492,"activeCount":67},[],{"trials":1494,"activeCount":67},[1495],{"nctId":1496,"briefTitle":1497,"status":149,"phases":1498,"primaryCompletion":1499,"completion":1499,"start":198,"enrollment":1500,"conditions":1501,"interventions":1504},"NCT01884844","Vitamin D Supplementation for Bipolar Depression",[60],"2015-08",33,[1502,1503],"Bipolar Disorder","Bipolar Depression",[1481],{"intervention":1506,"totalTrials":63,"cells":1507},"Fitbit Care intervention arm",{"EARLY_PHASE1":1508,"PHASE1":1510,"PHASE2":1512,"PHASE3":1514,"PHASE4":1516,"NA":1518},{"trials":1509,"activeCount":67},[],{"trials":1511,"activeCount":67},[],{"trials":1513,"activeCount":67},[],{"trials":1515,"activeCount":67},[],{"trials":1517,"activeCount":67},[],{"trials":1519,"activeCount":67},[1520],{"nctId":1521,"briefTitle":1522,"status":149,"phases":1523,"primaryCompletion":1524,"completion":1524,"start":1525,"enrollment":1526,"conditions":1527,"interventions":1529},"NCT04712383","Impact of Wearable Health Devices and Wellness Behavior Change Support on Health Outcomes and Healthcare Costs",[60],"2022-01-18","2021-01-13",597,[1528],"Health Behavior",[1506],{"intervention":1531,"totalTrials":63,"cells":1532},"DNA Analysis",{"EARLY_PHASE1":1533,"PHASE1":1535,"PHASE2":1537,"PHASE3":1539,"PHASE4":1541,"NA":1543},{"trials":1534,"activeCount":67},[],{"trials":1536,"activeCount":67},[],{"trials":1538,"activeCount":67},[],{"trials":1540,"activeCount":67},[],{"trials":1542,"activeCount":67},[],{"trials":1544,"activeCount":67},[1545],{"nctId":1546,"briefTitle":1547,"status":149,"phases":1548,"primaryCompletion":1549,"completion":1550,"start":1551,"enrollment":1552,"conditions":1553,"interventions":1557},"NCT04273672","Speech, Linguistic and Acoustic Markers in Parkinson's Disease",[],"2023-09-01","2025-02-28","2020-01-13",58,[1554,1555,1556],"Parkinson Disease","Cognitive Impairment, Mild","Speech",[1531],{"intervention":1559,"totalTrials":63,"cells":1560},"Ergocalciferols",{"EARLY_PHASE1":1561,"PHASE1":1563,"PHASE2":1565,"PHASE3":1567,"PHASE4":1569,"NA":1571},{"trials":1562,"activeCount":67},[],{"trials":1564,"activeCount":67},[],{"trials":1566,"activeCount":67},[],{"trials":1568,"activeCount":67},[],{"trials":1570,"activeCount":67},[],{"trials":1572,"activeCount":67},[1573],{"nctId":1574,"briefTitle":1575,"status":149,"phases":1576,"primaryCompletion":1577,"completion":1577,"start":1578,"enrollment":16,"conditions":1579,"interventions":1582},"NCT01004354","Vitamin D Supplementation in Psychiatric Illnesses",[60],"2010-06","2009-06",[15,1580,1581,18,24],"Vitamin D Deficiency","Psychosis",[1559],{"intervention":1584,"totalTrials":63,"cells":1585},"Flulaval",{"EARLY_PHASE1":1586,"PHASE1":1588,"PHASE2":1590,"PHASE3":1592,"PHASE4":1594,"NA":1596},{"trials":1587,"activeCount":67},[],{"trials":1589,"activeCount":67},[],{"trials":1591,"activeCount":67},[],{"trials":1593,"activeCount":67},[],{"trials":1595,"activeCount":67},[],{"trials":1597,"activeCount":67},[1598],{"nctId":1599,"briefTitle":1600,"status":149,"phases":1601,"primaryCompletion":1602,"completion":1602,"start":1603,"enrollment":1604,"conditions":1605,"interventions":1607},"NCT00902278","Immune Responses Induced by Different Licensed Influenza Vaccines",[60],"2016-04","2008-10",193,[1606],"Immune Response",[1584,1608,1609,1610,1611],"Fluvirin","Fluzone","Fluarix","Afluria",{"intervention":1608,"totalTrials":63,"cells":1613},{"EARLY_PHASE1":1614,"PHASE1":1616,"PHASE2":1618,"PHASE3":1620,"PHASE4":1622,"NA":1624},{"trials":1615,"activeCount":67},[],{"trials":1617,"activeCount":67},[],{"trials":1619,"activeCount":67},[],{"trials":1621,"activeCount":67},[],{"trials":1623,"activeCount":67},[],{"trials":1625,"activeCount":67},[1626],{"nctId":1599,"briefTitle":1600,"status":149,"phases":1627,"primaryCompletion":1602,"completion":1602,"start":1603,"enrollment":1604,"conditions":1628,"interventions":1629},[60],[1606],[1584,1608,1609,1610,1611],{"intervention":1609,"totalTrials":63,"cells":1631},{"EARLY_PHASE1":1632,"PHASE1":1634,"PHASE2":1636,"PHASE3":1638,"PHASE4":1640,"NA":1642},{"trials":1633,"activeCount":67},[],{"trials":1635,"activeCount":67},[],{"trials":1637,"activeCount":67},[],{"trials":1639,"activeCount":67},[],{"trials":1641,"activeCount":67},[],{"trials":1643,"activeCount":67},[1644],{"nctId":1599,"briefTitle":1600,"status":149,"phases":1645,"primaryCompletion":1602,"completion":1602,"start":1603,"enrollment":1604,"conditions":1646,"interventions":1647},[60],[1606],[1584,1608,1609,1610,1611],{"intervention":1610,"totalTrials":63,"cells":1649},{"EARLY_PHASE1":1650,"PHASE1":1652,"PHASE2":1654,"PHASE3":1656,"PHASE4":1658,"NA":1660},{"trials":1651,"activeCount":67},[],{"trials":1653,"activeCount":67},[],{"trials":1655,"activeCount":67},[],{"trials":1657,"activeCount":67},[],{"trials":1659,"activeCount":67},[],{"trials":1661,"activeCount":67},[1662],{"nctId":1599,"briefTitle":1600,"status":149,"phases":1663,"primaryCompletion":1602,"completion":1602,"start":1603,"enrollment":1604,"conditions":1664,"interventions":1665},[60],[1606],[1584,1608,1609,1610,1611],{"intervention":1611,"totalTrials":63,"cells":1667},{"EARLY_PHASE1":1668,"PHASE1":1670,"PHASE2":1672,"PHASE3":1674,"PHASE4":1676,"NA":1678},{"trials":1669,"activeCount":67},[],{"trials":1671,"activeCount":67},[],{"trials":1673,"activeCount":67},[],{"trials":1675,"activeCount":67},[],{"trials":1677,"activeCount":67},[],{"trials":1679,"activeCount":67},[1680],{"nctId":1599,"briefTitle":1600,"status":149,"phases":1681,"primaryCompletion":1602,"completion":1602,"start":1603,"enrollment":1604,"conditions":1682,"interventions":1683},[60],[1606],[1584,1608,1609,1610,1611],{"intervention":1685,"totalTrials":63,"cells":1686},"Bupivacaine",{"EARLY_PHASE1":1687,"PHASE1":1689,"PHASE2":1691,"PHASE3":1693,"PHASE4":1695,"NA":1697},{"trials":1688,"activeCount":67},[],{"trials":1690,"activeCount":67},[],{"trials":1692,"activeCount":67},[],{"trials":1694,"activeCount":67},[],{"trials":1696,"activeCount":67},[],{"trials":1698,"activeCount":67},[1699],{"nctId":1700,"briefTitle":1701,"status":149,"phases":1702,"primaryCompletion":1703,"completion":1703,"start":1201,"enrollment":1704,"conditions":1705,"interventions":1707},"NCT01583166","Voiding Function After Mid-Urethral Slings With and Without Local Anesthetic: Randomized Controlled Trial",[60],"2016-05",90,[1706],"Stress Urinary Incontinence",[1685,1708,1709],"Saline","Epinephrine",{"intervention":1708,"totalTrials":63,"cells":1711},{"EARLY_PHASE1":1712,"PHASE1":1714,"PHASE2":1716,"PHASE3":1718,"PHASE4":1720,"NA":1722},{"trials":1713,"activeCount":67},[],{"trials":1715,"activeCount":67},[],{"trials":1717,"activeCount":67},[],{"trials":1719,"activeCount":67},[],{"trials":1721,"activeCount":67},[],{"trials":1723,"activeCount":67},[1724],{"nctId":1700,"briefTitle":1701,"status":149,"phases":1725,"primaryCompletion":1703,"completion":1703,"start":1201,"enrollment":1704,"conditions":1726,"interventions":1727},[60],[1706],[1685,1708,1709],{"intervention":1709,"totalTrials":63,"cells":1729},{"EARLY_PHASE1":1730,"PHASE1":1732,"PHASE2":1734,"PHASE3":1736,"PHASE4":1738,"NA":1740},{"trials":1731,"activeCount":67},[],{"trials":1733,"activeCount":67},[],{"trials":1735,"activeCount":67},[],{"trials":1737,"activeCount":67},[],{"trials":1739,"activeCount":67},[],{"trials":1741,"activeCount":67},[1742],{"nctId":1700,"briefTitle":1701,"status":149,"phases":1743,"primaryCompletion":1703,"completion":1703,"start":1201,"enrollment":1704,"conditions":1744,"interventions":1745},[60],[1706],[1685,1708,1709],{"intervention":1747,"totalTrials":63,"cells":1748},"Helium-3",{"EARLY_PHASE1":1749,"PHASE1":1751,"PHASE2":1753,"PHASE3":1755,"PHASE4":1757,"NA":1759},{"trials":1750,"activeCount":67},[],{"trials":1752,"activeCount":67},[],{"trials":1754,"activeCount":67},[],{"trials":1756,"activeCount":67},[],{"trials":1758,"activeCount":67},[],{"trials":1760,"activeCount":67},[1761],{"nctId":1762,"briefTitle":1763,"status":537,"phases":1764,"primaryCompletion":1765,"completion":1765,"start":1766,"enrollment":67,"conditions":1767,"interventions":1769},"NCT00846014","Asthma Exacerbation and Helium-3 MRI",[60],"2011-08","2009-01",[1768],"Asthma Exacerbation",[1747],{"intervention":1479,"totalTrials":63,"cells":1771},{"EARLY_PHASE1":1772,"PHASE1":1774,"PHASE2":1776,"PHASE3":1778,"PHASE4":1780,"NA":1782},{"trials":1773,"activeCount":67},[],{"trials":1775,"activeCount":67},[],{"trials":1777,"activeCount":67},[],{"trials":1779,"activeCount":67},[],{"trials":1781,"activeCount":67},[],{"trials":1783,"activeCount":67},[1784],{"nctId":1473,"briefTitle":1474,"status":149,"phases":1785,"primaryCompletion":1467,"completion":1467,"start":1202,"enrollment":9,"conditions":1786,"interventions":1787},[60],[1477],[1449,1479],{"intervention":1789,"totalTrials":63,"cells":1790},"clopidogrel + aspirin",{"EARLY_PHASE1":1791,"PHASE1":1793,"PHASE2":1795,"PHASE3":1797,"PHASE4":1799,"NA":1801},{"trials":1792,"activeCount":67},[],{"trials":1794,"activeCount":67},[],{"trials":1796,"activeCount":67},[],{"trials":1798,"activeCount":67},[],{"trials":1800,"activeCount":67},[],{"trials":1802,"activeCount":67},[1803],{"nctId":1804,"briefTitle":1805,"status":149,"phases":1806,"primaryCompletion":1807,"completion":1807,"start":1808,"enrollment":1809,"conditions":1810,"interventions":1813},"NCT00619073","PACT (Platelet Activity After Clopidogrel Termination)",[60],"2009-05","2008-04",15,[1811,1812],"Blood Platelets","Clopidogrel",[1789,1814],"Aspirin",{"intervention":1814,"totalTrials":63,"cells":1816},{"EARLY_PHASE1":1817,"PHASE1":1819,"PHASE2":1821,"PHASE3":1823,"PHASE4":1825,"NA":1827},{"trials":1818,"activeCount":67},[],{"trials":1820,"activeCount":67},[],{"trials":1822,"activeCount":67},[],{"trials":1824,"activeCount":67},[],{"trials":1826,"activeCount":67},[],{"trials":1828,"activeCount":67},[1829],{"nctId":1804,"briefTitle":1805,"status":149,"phases":1830,"primaryCompletion":1807,"completion":1807,"start":1808,"enrollment":1809,"conditions":1831,"interventions":1832},[60],[1811,1812],[1789,1814]]